CLYM Climb Bio Inc.

Price (delayed)

$10.85

Market cap

$621.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$613.4M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 16
Highlights
CLYM's quick ratio has soared by 93% YoY and by 86% from the previous quarter
Climb Bio's EPS has soared by 65% YoY and by 13% from the previous quarter
Climb Bio's equity has decreased by 23% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of CLYM

CLYM stock price

How has the Climb Bio stock price performed over time
Intraday
3.93%
1 week
-4.32%
1 month
11.97%
1 year
741.09%
YTD
171.25%
QTD
58.39%

Financial performance

How have Climb Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.08M
Net income
-$52.79M
Gross margin
N/A
Net margin
N/A
CLYM's net income is up by 43% year-on-year and by 12% since the previous quarter
The operating income has grown by 41% YoY and by 12% from the previous quarter

Price vs fundamentals

How does CLYM's price correlate with its fundamentals

Growth

What is Climb Bio's growth rate over time

Valuation

What is Climb Bio stock price valuation
P/E
N/A
P/B
3.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Climb Bio's EPS has soared by 65% YoY and by 13% from the previous quarter
The price to book (P/B) is 159% more than the last 4 quarters average of 1.3
Climb Bio's equity has decreased by 23% YoY and by 8% from the previous quarter

Efficiency

How efficient is Climb Bio business performance
CLYM's ROIC has soared by 65% YoY and by 8% QoQ
The return on assets rose by 29% year-on-year and by 6% since the previous quarter
The company's return on equity rose by 28% YoY and by 6% QoQ

Dividends

What is CLYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLYM.

Financial health

How did Climb Bio financials performed over time
The current ratio has soared by 96% YoY and by 84% from the previous quarter
CLYM's quick ratio has soared by 93% YoY and by 86% from the previous quarter
CLYM's debt is 100% smaller than its equity
Climb Bio's equity has decreased by 23% YoY and by 8% from the previous quarter
CLYM's debt is down by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.